Yabao,
Changzhou Le Sun Pharmaceuticals to develop early-stage cancer drugs
China-based Yabao
Pharmaceutical has entered into a strategic partnership with Changzhou Le Sun
Pharmaceuticals to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008,
which currently is under pre-clinical development.
Under the deal, Yabao
secured exclusive rights to develop and commercialize LS-008 in China while Le
Sun retains majority of exclusive rights in all other markets.
Both the firms will
jointly determine the strategic development plan, which will be performed
primarily by Yabao in China under global GLP, GMP and GCP standards.
According to the
companies, the partnership helps in accelerating the development of an oncology
compound in China for the globe, by leveraging the complementary strengths of a
Chinese pharmaceutical firm and a world-class medicinal chemistry and drug
discovery expertise.
Yabao Pharmaceutical
president of R&D Peng Wang said PLK/PI3K dual inhibition represents a new
and promising approach to developing new drugs for several cancers, with the
most advanced compounds currently in phase III global development.
"We strongly believe
LS-008 has potential to be best-in-class," Wang said.
"This ground-breaking
partnership with Changzhou Le Sun Pharmaceuticals is an important sign of
Yabao's growing commitment to partner the best science and leverage Yabao's
strong clinical and regulatory capabilities to bring novel pharmaceuticals to
patients suffering from serious diseases in China and in the world."
Changzhou Le Sun
Pharmaceuticals founder and president professor Shudong Wang said:
"Working together we are building on the strengths of both parties to
develop potential new drug and help patients globally."
No comments:
Post a Comment